Easton Pharmaceuticals Enters Into Cancer Drug Industry by Acquiring Initial Minority Ownership Interest in Experimental Canc...
November 06 2013 - 1:38PM
Marketwired
Easton Pharmaceuticals Enters Into Cancer Drug Industry by
Acquiring Initial Minority Ownership Interest in Experimental
Cancer Drug "XILIVE" With 12 Month Option to Purchase Remaining
Interest; Preliminary Feedback Extremely Promising
BELLPORT, NY--(Marketwired - Nov 6, 2013) - Easton
Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company
that designs, develops, and markets an array of topically-delivered
drugs and therapeutic healthcare products announced today It has
purchased an initial 10 percent ownership interest in experimental
cancer drug "XILIVE" From a private Canadian company and
individual.
Easton Pharmaceuticals 10 percent cash purchase of "Xilive", an
early stage, experimental cancer drug was finalized after
completing a conditional financing with an accredited
non-affiliated investor with additional funds committed. The
purchase agreement for "Xilive" provides the company with an
exclusive option to purchase the remaining ownership interest,
exercisable anytime over the next 12 month time period.
Xilive is a drug that was developed 7 years ago and utilized
under compassionate grounds on two individuals suffering from
various forms of advanced stage cancer. The first individual, age
57, suffering from Lymphoma was administered "Xilive"
simultaneously with chemotherapy and previously given a 50/50
chance of survival by physicians. The second individual, in his mid
60's, suffering from lung cancer was solely administered "Xilive"
after being diagnosed and advised by physicians that the cancer was
in its advanced stages where chemotherapy and surgery we're no
longer considered a viable medical treatment option. Both
individuals have thus far reached and past the critical 5 years or
more time period after being diagnosed and advised that their
cancers were in remission. One of the individuals suffering from
advanced stage lymphoma has been diagnosed cancer free for more
than 5 years. Both individuals continue to willingly use "Xilive"
as a maintenance and preventative treatment.
In Canada as well as in various states in the United States and
most Western European countries, there exist laws that allow for
patients diagnosed with terminal cancer or other types of terminal
diseases to gain access to experimental drugs for compassionate
reasons. Easton Pharmaceuticals and the current majority owner(s)
and developers believe "Xilive" can be initially used for a fee
under these conditions, which would be concurrent with any type of
in-house safety and efficacy trials the company wishes to proceed
with. Additional details to be announced.
Regardless of the positive outcomes, neither person was
administered "Xilive" under the supervision of any specialized
medical physicians. Both Easton Pharmaceuticals and the current
majority owner(s) and developers of "Xilive" have not previously,
nor are presently claiming "Xilive" positively treated the cancers
of these individuals. There have not been any third party
independent clinical trials or testing of any form to confirm
"Xilive" positively treated and affected these individuals or will
be of any future benefit to any other persons diagnosed with any
form of cancer or condition who willfully agree to have "Xilive"
administered to them as a possible treatment option. Other factors
not presently known may have contributed to the dramatic
un-expected positive reversal in condition(s).
It is the company's intention to move forward to undertake
in-house testing on pre selected cancer patients under the
supervision of specialized independent medical physicians prior to
formulating a strategy to move the drug to the next level of
testing and clinical trials. In-house testing will also need
to be finalized prior to any decisions on whether the company
exercises its option to purchase any additional ownership interest
in "Xilive". Regardless of the amount, if any, the company chooses
to additionally purchase of "Xilive", the agreement calls for a 15
percent royalty to be paid to the current majority owner(s) should
the drug eventually be proven as safe and effective and reach a
stage where it will generate any amount of revenues. Additional
news involving details on planned in-house trials and additional
committed financing are expected to be announced shortly including
the additions of new board members and consultants better
specialized in being able to bring such a drug and any testing
programs forward.
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company
that designs, develops, and markets what it believes to be a
premium array of topically-delivered Drugs and therapeutic
healthcare products, focused on Cancer and other health issues
related to male and female sexual dysfunction, wound healing, pain,
motion sickness, scar and stretch marks, cellulite, varicose veins
and other conditions. The company's gel formulation is thought to
be an innovative and unique transdermal delivery system. Easton
Pharmaceuticals product "VIORRA" is an over-the-counter
aid for the treatment to restore and improve vaginal moisture and
elasticity which is believed to have a positive effect on women's
sexual desire and arousal, FSAD (Female Sexual Arousal Disorder)
the world market for these female conditions are in excess of $2
billion. VIORRA is a topical, daily-use product classified
by the FDA as containing Generally Recognized as Safe
ingredients.
For More Information Visit
http://www.eastonpharma.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "pleased," "plan," "confident that,"
"believe," "expect," "should", expect", "anticipate", "intent to"
and similar conditional expressions are intended to identify
forward-looking statements within the meaning of the Act and are
subject to the safe harbor created by the Act. Such statements are
subject to certain risks and uncertainties and actual results could
differ materially from those expressed in any of the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, market conditions, general acceptance of
the company's products and technologies, competitive factors, the
ability to successfully complete additional or adequate financing
and other risks and uncertainties as stated in the company's
financial reports and filings which all investors are advised to
view.
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Sep 2023 to Sep 2024